Literature DB >> 20602726

Brief PANSS to assess and monitor the overall severity of schizophrenia.

Nobutomo Yamamoto1, Toshiya Inada, Shinji Shimodera, Ippei Morokuma, Toshiaki A Furukawa.   

Abstract

AIMS: The aim of the present study was to develop a subscale of the Positive and Negative Syndrome Scale (PANSS) that would be brief and sensitive to changes in the clinical features of schizophrenia (i.e. the Brief PANSS, or bPANSS).
METHODS: The PANSS before and after treatment, and the Clinical Global Impression-Change (CGI-C) was rated for 714 schizophrenia patients. Of these, Clinical Global Impression-Severity (CGI-S) was also evaluated in 30 of these patients. The bPANSS items were extracted from full PANSS items based on the following aims: (i) to develop a brief scale; (ii) to develop a scale sensitive to changes resulting from antipsychotic treatment; and (iii) to reflect the broad spectrum of schizophrenia symptoms.
RESULTS: The following six items were extracted to serve as the bPANSS: delusion, suspiciousness, emotional withdrawal, passive/apathetic social withdrawal, tension, and unusual thought content. The coefficients of correlation between the bPANSS and full PANSS before and after treatment were 0.86 and 0.92, respectively (both P < 0.001). The coefficient of correlation between the degrees of change in the scores for the bPANSS and the full PANSS was 0.93 (P < 0.001), and that between delta bPANSS and CGI-C was 0.73 (P < 0.001).
CONCLUSIONS: bPANSS is able to capture the overall clinical features of schizophrenia within a short assessment period.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20602726     DOI: 10.1111/j.1440-1819.2010.02081.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  3 in total

Review 1.  Are Shorter Versions of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review.

Authors:  Jean-Pierre Lindenmayer
Journal:  Innov Clin Neurosci       Date:  2017-12-01

2.  Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study.

Authors:  Mustafa Yildiz; Aysel Incedere; Mehmet Buğrahan Gürcan; Emre Osman
Journal:  Noro Psikiyatr Ars       Date:  2021-08-04       Impact factor: 1.339

3.  Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication.

Authors:  Joanna Moncrieff; Kiran Azam; Sonia Johnson; Louise Marston; Nicola Morant; Katherine Darton; Neil Wood
Journal:  BMC Psychiatry       Date:  2016-07-04       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.